Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry

RB. Schnabel, P. Ameri, JM. Siller-Matula, I. Diemberger, M. Gwechenberger, L. Pecen, MC. Manu, J. Souza, R. De Caterina, P. Kirchhof

. 2023 ; 25 (9) : . [pub] 2023Aug02

Language English Country England, Great Britain

Document type Observational Study, Journal Article

Persistent link   https://www.medvik.cz/link/bmc24001267

Grant support
European Research Council - International

AIMS: Heart failure (HF) is a risk factor for major adverse events in atrial fibrillation (AF). Whether this risk persists on non-vitamin K antagonist oral anticoagulants (NOACs) and varies according to left ventricular ejection fraction (LVEF) is debated. METHODS AND RESULTS: We investigated the relation of HF in the ETNA-AF-Europe registry, a prospective, multicentre, observational study with an overall 4-year follow-up of edoxaban-treated AF patients. We report 2-year follow-up for ischaemic stroke/transient ischaemic attack (TIA)/systemic embolic events (SEE), major bleeding, and mortality. Of the 13 133 patients, 1854 (14.1%) had HF. Left ventricular ejection fraction was available for 82.4% of HF patients and was <40% in 671 (43.9%) and ≥40% in 857 (56.1%). Patients with HF were older, more often men, and had more comorbidities. Annualized event rates (AnERs) of any stroke/SEE were 0.86%/year and 0.67%/year in patients with and without HF. Compared with patients without HF, those with HF also had higher AnERs for major bleeding (1.73%/year vs. 0.86%/year) and all-cause death (8.30%/year vs. 3.17%/year). Multivariate Cox proportional models confirmed HF as a significant predictor of major bleeding [hazard ratio (HR) 1.65, 95% confidence interval (CI): 1.20-2.26] and all-cause death [HF with LVEF <40% (HR 2.42, 95% CI: 1.95-3.00) and HF with LVEF ≥40% (HR 1.80, 95% CI: 1.45-2.23)] but not of ischaemic stroke/TIA/SEE. CONCLUSION: Anticoagulated patients with HF at baseline featured higher rates of major bleeding and all-cause death, requiring optimized management and novel preventive strategies. NOAC treatment was similarly effective in reducing risk of ischaemic events in patients with or without concomitant HF.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001267
003      
CZ-PrNML
005      
20240213094506.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/europace/euad280 $2 doi
035    __
$a (PubMed)37713182
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Schnabel, Renate B $u Department of Cardiology, University Clinic Hamburg-Eppendorf, University Heart and Vascular Centre Hamburg-Eppendorf, Buildung O50, Martinistrasse 52, 20246 Hamburg, Germany $u DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Potsdamer Str, 5810785 Berlin, Germany $1 https://orcid.org/0000000171709509
245    10
$a Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry / $c RB. Schnabel, P. Ameri, JM. Siller-Matula, I. Diemberger, M. Gwechenberger, L. Pecen, MC. Manu, J. Souza, R. De Caterina, P. Kirchhof
520    9_
$a AIMS: Heart failure (HF) is a risk factor for major adverse events in atrial fibrillation (AF). Whether this risk persists on non-vitamin K antagonist oral anticoagulants (NOACs) and varies according to left ventricular ejection fraction (LVEF) is debated. METHODS AND RESULTS: We investigated the relation of HF in the ETNA-AF-Europe registry, a prospective, multicentre, observational study with an overall 4-year follow-up of edoxaban-treated AF patients. We report 2-year follow-up for ischaemic stroke/transient ischaemic attack (TIA)/systemic embolic events (SEE), major bleeding, and mortality. Of the 13 133 patients, 1854 (14.1%) had HF. Left ventricular ejection fraction was available for 82.4% of HF patients and was <40% in 671 (43.9%) and ≥40% in 857 (56.1%). Patients with HF were older, more often men, and had more comorbidities. Annualized event rates (AnERs) of any stroke/SEE were 0.86%/year and 0.67%/year in patients with and without HF. Compared with patients without HF, those with HF also had higher AnERs for major bleeding (1.73%/year vs. 0.86%/year) and all-cause death (8.30%/year vs. 3.17%/year). Multivariate Cox proportional models confirmed HF as a significant predictor of major bleeding [hazard ratio (HR) 1.65, 95% confidence interval (CI): 1.20-2.26] and all-cause death [HF with LVEF <40% (HR 2.42, 95% CI: 1.95-3.00) and HF with LVEF ≥40% (HR 1.80, 95% CI: 1.45-2.23)] but not of ischaemic stroke/TIA/SEE. CONCLUSION: Anticoagulated patients with HF at baseline featured higher rates of major bleeding and all-cause death, requiring optimized management and novel preventive strategies. NOAC treatment was similarly effective in reducing risk of ischaemic events in patients with or without concomitant HF.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a fibrilace síní $x komplikace $x diagnóza $x farmakoterapie $7 D001281
650    12
$a cévní mozková příhoda $x diagnóza $x epidemiologie $x etiologie $7 D020521
650    _2
$a antikoagulancia $x škodlivé účinky $7 D000925
650    12
$a tranzitorní ischemická ataka $x diagnóza $x epidemiologie $x prevence a kontrola $7 D002546
650    12
$a ischemie mozku $7 D002545
650    _2
$a prospektivní studie $7 D011446
650    _2
$a tepový objem $x fyziologie $7 D013318
650    _2
$a aplikace orální $7 D000284
650    _2
$a funkce levé komory srdeční $7 D016277
650    _2
$a krvácení $x chemicky indukované $7 D006470
650    12
$a embolie $7 D004617
650    12
$a ischemická cévní mozková příhoda $7 D000083242
650    12
$a srdeční selhání $x diagnóza $x epidemiologie $7 D006333
650    _2
$a registrace $7 D012042
655    _2
$a pozorovací studie $7 D064888
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ameri, Pietro $u Department of Internal Medicine, University of Genova, Genova, Italy $u Cardiac, Thoracic and Vascular Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy $1 https://orcid.org/0000000171677287
700    1_
$a Siller-Matula, Jolanta M $u Department of Cardiology, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000160411635
700    1_
$a Diemberger, Igor $u Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy $u Unit of Cardiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy $1 https://orcid.org/0000000238233809
700    1_
$a Gwechenberger, Marianne $u Department of Cardiology, Medical University of Vienna, Vienna, Austria
700    1_
$a Pecen, Ladislav $u Czech Academy of Science, Institute of Computer Sciences, Prague, Czech Republic $u Department of Immunochemistry Diagnostics, University Hospital Pilsen, Pilsen, Czech Republic $1 https://orcid.org/0000000198273178
700    1_
$a Manu, Marius Constantin $u Daiichi Sankyo Europe GmbH, Munich, Germany
700    1_
$a Souza, José $u Daiichi Sankyo Europe GmbH, Munich, Germany
700    1_
$a De Caterina, Raffaele $u Cardiology Division, Pisa University Hospital, Pisa, Italy $u Fondazione Villa Serena per la Ricerca, Pescara, Italy $1 https://orcid.org/000000031637574X $7 uk2006353696
700    1_
$a Kirchhof, Paulus $u Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK $u Department of Cardiology, University Heart and Vascular Centre Hamburg, University Medical Centre Hamburg Eppendorf, Hamburg, Germany $u German Center for Cardiovascular Sciences (DZHK), partner site Hamburg/Kiel/Lübeck, Germany $1 https://orcid.org/0000000218810197
773    0_
$w MED00149837 $t Europace $x 1532-2092 $g Roč. 25, č. 9 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37713182 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213094503 $b ABA008
999    __
$a ok $b bmc $g 2049719 $s 1210961
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 25 $c 9 $e 2023Aug02 $i 1532-2092 $m Europace $n Europace $x MED00149837
GRA    __
$p European Research Council $2 International
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options